- Home
- SKYQ vs QNRX Comparison
SKYQ vs QNRX Comparison
Compare SKYQ & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYQ
- QNRX
- Stock Information
- Founded
- SKYQ 2019
- QNRX 2018
- Country
- SKYQ United States
- QNRX United States
- Employees
- SKYQ N/A
- QNRX N/A
- Industry
- SKYQ
- QNRX Medical/Dental Instruments
- Sector
- SKYQ
- QNRX Health Care
- Exchange
- SKYQ NYSE
- QNRX Nasdaq
- Market Cap
- SKYQ 2.0M
- QNRX 2.1M
- IPO Year
- SKYQ N/A
- QNRX N/A
- Fundamental
- Price
- SKYQ $1.90
- QNRX $0.62
- Analyst Decision
- SKYQ
- QNRX Strong Buy
- Analyst Count
- SKYQ 0
- QNRX 1
- Target Price
- SKYQ N/A
- QNRX $4.00
- AVG Volume (30 Days)
- SKYQ 173.8K
- QNRX 486.4K
- Earning Date
- SKYQ 11-26-2024
- QNRX 11-07-2024
- Dividend Yield
- SKYQ N/A
- QNRX N/A
- EPS Growth
- SKYQ N/A
- QNRX N/A
- EPS
- SKYQ N/A
- QNRX N/A
- Revenue
- SKYQ $30,766,012.00
- QNRX N/A
- Revenue This Year
- SKYQ N/A
- QNRX N/A
- Revenue Next Year
- SKYQ N/A
- QNRX N/A
- P/E Ratio
- SKYQ N/A
- QNRX N/A
- Revenue Growth
- SKYQ N/A
- QNRX N/A
- 52 Week Low
- SKYQ $1.51
- QNRX $0.48
- 52 Week High
- SKYQ $5.49
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- SKYQ N/A
- QNRX 43.57
- Support Level
- SKYQ N/A
- QNRX $0.60
- Resistance Level
- SKYQ N/A
- QNRX $0.77
- Average True Range (ATR)
- SKYQ 0.00
- QNRX 0.07
- MACD
- SKYQ 0.00
- QNRX -0.02
- Stochastic Oscillator
- SKYQ 0.00
- QNRX 12.98
About SKYQ SKY QUARRY INC
Sky Quarry Inc is a development-stage oil-producing and refining company. The company along with its subsidiaries is engaged in deploying technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated soils. The recycling and production of oil from asphalt shingles is expected to reduce the dependence on landfills for the disposal of waste and to also reduce dependence on foreign and domestic virgin crude oil extraction for industrial uses.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.